>Antibody-Drug Conjugates (ADCs): the Magic Bullets for Treatment
In recent years, Antibody-Drug Conjugates (ADCs) may serve as a novel therapeutic modality for many cancer patients. Indeed, three key elements define an ADC: the antibody directed against a specific tumor antigen, the cytotoxin/payload and the cleavable/uncleavable linker connecting the payload to the antibody . Specific target recognition and effective toxin make ADCs veritable "magic bullet". These 'magic bullets' deliver treatment that is both highly targeted and highly potent, seeking out and attacking cancerous cells throughout the body, while avoiding harm to healthy cells. Reasonable selection of targets, antibody, linker, payload, and their rational combinations are crucial for an effective treatment. Among these elements, target selection, linker selection and evaluating preclinical /clinical efficacy are considered critical factors for ADCs development. >>> Download the ebook: Key point of ADCs design
Suitable for immunization / antibody screening / cross-reactivity/cell-based assay/QC.
Exclusive LIV-1 proteins:
✔ Multiple species: Human, Mouse, Cynomolgus, Rat, etc.;
✔ Expression sequences were designed based on the SGN-LIV1A binding epitope.
>> Comprehensive products: anti-MMAE antibodies and anti-idiotypic antibodies;
>> High specificity & affinity;
>> High sensitivity & stability.
✔ Positive reference of ADCs preclinical / clinical immunogenicity;
✔ PK analysis;
✔ Anti-payload antibodies: Qualitative detection of DAR value.
The activity of anti-MMAE monoclonal antibody (Cat.No.MME-M5252) is verified by binding to Disitamab Vedotin (RC-48) with a linear range of 0.1-2 ng/mL.
>> Proteins offered for free;
>> Experienced R&D technical team;
>> Personalized solution design and report format.
Monoclonal/polyclonal anti-idiotype antibody, pharmacokinetic and immunogenicity test kit.
✔ ADA assay: Perfect as Calibrator;
✔ PK assay: Quantitative analysis of therapeutic antibody in matrix.
ADC target proteins
Proteases for peptide linker
Tools for ADCs PK analysis
|Cathepsin||Cathepsin B||CTB-H5222||Human Cathepsin B / CTSB Protein, His Tag (active enzyme)|
|Cathepsin L||CT1-H5222||Human Cathepsin L / CTSL1 Protein, His Tag|
|Cathepsin S||CTS-H5224||Human Cathepsin S / CTSS Protein, His Tag|
|PLAU||PLAU||PLU-H5229||Human PLAU / uPA Protein, His Tag|
|PLAU||PLU-H5228||Human PLAU / uPA Protein, His Tag (activated by trypsin) (active enzyme)|
|MMPs||MMP-1||MM1-H5222||Human MMP-1 Protein, His Tag|
|MMP-2||MM2-H5225||Human MMP-2 Protein, His Tag|
|MMP-2||MM2-H82E3||Biotinylated Human MMP-2 Protein, His,Avitag™|
|MMP-2||MM2-M52H3||Mouse MMP-2 Protein, His Tag|
|MMP-9||MM9-H5221||Human MMP-9 Protein, His Tag (active enzyme)|
|Cat.No.||Product description||Neutralizing activity||Affinity KD, nM||Application|
|MME-M5252NEW||Anti-MMAE Antibodies||/||/||PK assay; ELISA|
|ADB-Y19||Anti-Adalimumab Antibodies||Neutralizing Antibody||0.0013||ADA assay; Neutralizing assay; Indirect ELISA|
|ADB-Y23b||Anti-Adalimumab Antibodies||Non-Neutralizing Antibody||/||PK bridging ELISA with ADB-BY17; Indirect ELISA|
|ADB-BY17||Biotinylated Anti-Adalimumab Antibodies||Neutralizing Antibody||/||PK bridging ELISA with ADB-Y23b|
|BEB-Y9||Anti-Bevacizumab Antibodies||Neutralizing Antibody||1.92||ADA assay; Indirect ELISA|
|BEB-Y10||Anti-Bevacizumab Antibodies||Neutralizing Antibody||/||PK bridging ELISA with BEB-BY13; Neutralizing assay; Indirect ELISA|
|BEB-BY13||Biotinylated Anti-Bevacizumab Antibodies||Neutralizing Antibody||/||PK bridging ELISA with BEB-Y10|
|CEB-Y27||Anti-Cetuximab Antibodies||Neutralizing Antibody||0.007||ADA assay; Neutralizing assay; Indirect ELISA|
|CEB-Y29||Anti-Cetuximab Antibodies||Neutralizing Antibody||/||PK bridging ELISA with CEB-BY31; Neutralizing assay; Indirect ELISA|
|CEB-BY31||Biotinylated Anti-Cetuximab Antibodies||Non-Neutralizing Antibody||/||PK bridging ELISA with CEB-Y29|
|RIB-Y35c||Anti-Rituximab Antibodies||Neutralizing Antibody||/||ADA assay; Neutralizing assay; Indirect ELISA|
|TRB-Y1b||Anti-Trastuzumab Antibodies||Neutralizing Antibody||/||PK bridging ELISA with TRB-Y5b; Neutralizing assay; Indirect ELISA|
|TRB-Y5b||Anti-Trastuzumab Antibodies||Non-Neutralizing Antibody||/||PK bridging ELISA with TRB-Y1b|
The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
Immobilized Human TROP-2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
Immobilized Human PSMA, His Tag (Cat. No. PSA-H52H3) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.3-39 ng/mL (Routinely tested).
Anti-LIV-1 mAb captured on CM5 chip via anti-human IgG Fc antibody can bind Human LIV-1, His Tag (Cat. No. LV1-H5223) with an affinity constant of 5.24 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.
Loaded Mouse Nectin-4, His Tag (Cat. No. NE4-M52H3) on HIS1K Biosensor, can bind Human Nectin-1, Fc Tag (Cat. No. PV1-H5253) with an affinity constant of 0.12 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
2e5 of anti-ROR1 CAR-293 cells were stained with 100 μL of 10 μg/mL of Human / Cynomolgus / Rhesus macaque ROR1 (39-151, Ig-like domain), His Tag (Cat. No. RO1-H5221) and negative control protein respectively, washed and then followed by PE-anti-His Tag and analyzed with FACS (Routinely tested).
|Products||Cat.No：CTB-H5222 Human Cathepsin B / CTSB Protein, His Tag (active enzyme)||Cat.No：MM9-H5221 Human MMP-9 Protein, His Tag (active enzyme)|
|Hydrolyzed substrate||Fluorogenic peptide substrate Z-LR-AMC||Fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2|
|Enzymatic activity |
|> 2500||> 2500|
The EC50 value of anti-MMAE antibody to MMAE-conjugated hRS7 (MMAE-ADC) was 0.12 μg/ml. The unconjugated hRS7 antibody was used as negative control
Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Mouse Anti-MMAE Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).
|Antigen capture ELISA||CD20||Goat anti-human IgG||—||—||Simple and universal method|
|Anti-idiotypic capture ELISA||Anti-Rituximab Antibodies||Goat anti-human IgG||0.156-10||0.156||It is a simple method for extracting CD20|
|Bridging ELISA by anti-idiotypic antibodies||Anti-Rituximab Antibodies||Biotinylated Anti-Rituximab Antibodies||0.012-0.78||0.012||CD20 can be obtained with good sensitivity and low background noise|
This web search service is supported by Google Inc.